















































































































































































































- Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). *Antimicrob Agents Chemother* 2010; 54: 2953-9.
32. McGee L. The coming of age of niche vaccines? Effect of vaccines on resistance profiles in *Streptococcus pneumoniae*. *Curr Opin Microbiol*. 2007; 10: 473-8.
  33. Picazo J, Ruiz-Contreras J, Casado-Flores J, Giangaspro E, Del Castillo F, Hernández-Sampelayo T, Otheo E, Balboa F, Ríos E, Méndez C; Heracles Study Group. Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar. *Clin Vaccine Immunol*. 2011; 18: 89-94.
  34. Ardanuy C, Rolo D, Fenoll A, Tarrago D, Calatayud L, Liñares J. Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain. *J Antimicrob Chemother*. 2009; 64: 507-10.
  35. Picazo J, Ruiz-Contreras J, Hernandez B, Sanz F, Gutierrez A, Cercenado E, Meseguer MA, Delgado-Iribarren A, Rodriguez-Avial I, Méndez C. Clonal and clinical profile of *Streptococcus pneumoniae* serotype 19A causing pediatric invasive infections: a 2-year (2007-2009) laboratory-based surveillance in Madrid. *Vaccine*. 2011; 29: 1770-6.
  36. Macheboeuf P, Contreras-Martel C, Job V, Dideberg O, Dessen A. Penicillin binding proteins: key players in bacterial cell cycle and drug resistance processes. *FEMS Microbiol Rev*. 2006; 30: 673-91.
  37. Morris SK, Moss WJ, Halsey N. *Haemophilus influenzae* type b conjugate vaccine use and effectiveness. *Lancet Infect Dis* 2008; 8: 435-43.
  38. Erwin AL, Smith AL. Nontypeable *Haemophilus influenzae*: understanding virulence and commensal behavior. *Trends Microbiol* 2007; 15: 355-62.
  39. Murphy TF, Faden H, Bakaletz LO, Kyd JM, Forsgren A, Campos J, Virji M, Pelton SI. Nontypeable *Haemophilus influenzae* as a pathogen in children. *Pediatr Infect Dis J* 2009; 28: 43-8.

40. Murphy TF. *Haemophilus* infections. In: Mandell GL, Bennett JE and Dolin R (eds), Mandell, Douglas, Bennett's Principles and Practice of Infectious Diseases, 6th ed. Elsevier Inc., Philadelphia, PA, 2005.
41. St Sauver J, Marrs CF, Foxman B, Somsel P, Madera R, Gilsdorf JR. Risk factors for otitis media and carriage of multiple strains of *Haemophilus influenzae* and *Streptococcus pneumoniae*. Emerg Infect Dis 2000; 6: 622-30.
42. Margolis E, Yates A, Levin BR. The ecology of nasal colonization of *Streptococcus pneumoniae*, *Haemophilus influenzae* and *Staphylococcus aureus*: the role of competition and interactions with host's immune response. BMC Microbiol 2010; 10: 59.
43. Block SL, Hedrick J, Harrison CJ, Tyler R, Smith A, Findlay R, Keegan E. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J 2004; 23: 829-33.
44. Faden H, Duffy L, Wasielewski R, Wolf J, Krystofik D, Tung Y. Relationship between nasopharyngeal colonization and the development of otitis media in children. Tonawanda/Williamsville Pediatrics. J Infect Dis 1997; 175: 1440-5.
45. Hallström T, Riesbeck K. *Haemophilus influenzae* and the complement system. Trends Microbiol 2010; 18 :258-65.
46. Murphy TF, Sethi S, Klingman KL, Brueggemann AB, Doern GV. Simultaneous respiratory tract colonization by multiple strains of nontypeable *Haemophilus influenzae* in chronic obstructive pulmonary disease: implications for antibiotic therapy. J Infect Dis 1999; 180: 404-9.
47. Murphy TF. The role of bacteria in airway inflammation in exacerbations of chronic obstructive pulmonary disease. Curr Opin Infect Dis 2006; 19: 225-30.
48. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465-71.

49. Campos J, Garcia-Tornel S, Sanfeliu I. Susceptibility studies of multiply resistant *Haemophilus influenzae* isolated from pediatric patients and contacts. *Antimicrob Agents Chemother* 1984; 25: 706-9.
50. San Millan A, Garcia-Cobos S, Escudero JA, Hidalgo L, Gutierrez B, Carrilero L, Campos J, Gonzalez-Zorn B. *Haemophilus influenzae* clinical isolates with plasmid pB1000 bearing bla<sub>ROB-1</sub>: fitness cost and interspecies dissemination. *Antimicrob Agents Chemother* 2010; 54: 1506-11.
51. Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in *Haemophilus influenzae*. *Clin Microbiol Rev* 2007; 20: 368-89.
52. Bell SM, Plowman D. Mechanisms of ampicillin resistance in *Haemophilus influenzae* from respiratory tract. *Lancet* 1980; 1: 279-80.
53. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement. CLSI document M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA, USA, 2009.
54. Matic V, Bozdogan B, Jacobs MR, Ubukata K, Appelbaum PC. Contribution of beta-lactamase and PBP amino acid substitutions to amoxicillin/clavulanate resistance in beta-lactamase-positive, amoxicillin/clavulanate-resistant *Haemophilus influenzae*. *J Antimicrob Chemother* 2003; 52: 1018-21.
55. Albritton WL, Setlow JK, Slaney L. Transfer of *Haemophilus influenzae* chromosomal genes by cell-to-cell contact. *J Bacteriol* 1982; 152: 1066-70.
56. Takahata S, Ida T, Senju N, Sanbongi Y, Miyata A, Maebashi K, Hoshiko S. Horizontal gene transfer of *ftsI*, encoding penicillin-binding protein 3, in *Haemophilus influenzae*. *Antimicrob Agents Chemother* 2007; 51: 1589-95.
57. García-Cobos S, Campos J, Lázaro E, Román F, Cercenado E, García-Rey C, Pérez-Vázquez M, Oteo J, de Abajo F. Ampicillin-resistant non-beta-lactamase-producing *Haemophilus influenzae* in Spain: recent emergence of clonal isolates

- with increased resistance to cefotaxime and cefixime. *Antimicrob Agents Chemother* 2007; 51: 2564-73.
58. Sahm DF, Brown NP, Thornsberry C, Jones ME. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective. *Postgrad Med* 2008; 120(3 Suppl 1): 16-24.
  59. Sahm DF, Brown NP, Draghi DC, Evangelista AT, Yee YC, Thornsberry C. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005. *Postgrad Med* 2008; 120(3 Suppl 1): 8-15.
  60. Jansen WT, Verel A, Beitsma M, Verhoef J, Milatovic D. Longitudinal European surveillance study of antibiotic resistance of *Haemophilus influenzae*. *J Antimicrob Chemother* 2006; 58: 873-877.
  61. Darabi A, Hocquet D, Dowzicky MJ. Antimicrobial activity against *Streptococcus pneumoniae* and *Haemophilus influenzae* collected globally between 2004 and 2008 as part of the Tigecycline Evaluation and Surveillance Trial. *Diagn Microbiol Infect Dis* 2010; 67: 78-86.
  62. Witherden EA, Montgomery J, Henderson B, Tristram SG. Prevalence and genotypic characteristics of  $\beta$ -lactamase-negative ampicillin-resistant *Haemophilus influenzae* in Australia. *J Antimicrob Chemother* 2011; 66: 1013-5.
  63. Dabernat H, Seguy M, Faucon G, Delmas C. [Epidemiology of *Haemophilus influenzae* strains identified in 2001 in France, and assessment of their susceptibility to beta-lactams]. [Article in French]. *Med Mal Infect* 2004; 34: 97-101.
  64. Jansen WT, Verel A, Beitsma M, Verhoef J, Milatovic D. Surveillance study of the susceptibility of *Haemophilus influenzae* to various antibacterial agents in Europe and Canada. *Curr Med Res Opin* 2008; 24: 2853-61.
  65. Goto H, Shimada K, Ikemoto H, Oguri T; Study Group on Antimicrobial Susceptibility of Pathogens Isolated from Respiratory Infections. Antimicrobial



- susceptibility of pathogens isolated from more than 10,000 patients with infectious respiratory diseases: a 25-year longitudinal study. *J Infect Chemother* 2009; 15: 347-60.
66. Sawada K, Sato H, Arima M, Hoshino T. [Susceptibility testing for *Haemophilus influenzae* isolated from pediatric cases during 2004-2008]. [Article in Japanese]. *Kansenshogaku Zasshi* 2010; 84: 441-8.
  67. Kishii K, Chiba N, Morozumi M, Hamano-Hasegawa K, Kurokawa I, Masaki J, Ubukata K. Diverse mutations in the *ftsI* gene in ampicillin-resistant *Haemophilus influenzae* isolates from pediatric patients with acute otitis media. *J Infect Chemother* 2010; 16: 87-93.
  68. Ito M, Hotomi M, Maruyama Y, Hatano M, Sugimoto H, Yoshizaki T, Yamanaka N. Clonal spread of beta-lactamase-producing amoxicillin-clavulanate-resistant (BLPACR) strains of non-typeable *Haemophilus influenzae* among young children attending a day care in Japan. *Int J Pediatr Otorhinolaryngol* 2010; 74: 901-6.
  69. Musser JM, Shelburne SA 3rd. A decade of molecular pathogenomic analysis of group A Streptococcus. *J Clin Invest* 2009; 119: 2455-63.
  70. Bessen DE. Population biology of the human restricted pathogen, *Streptococcus pyogenes*. *Infect Genet Evol* 2009; 9: 581-93.
  71. Bisno AL, Stevens DL. *Streptococcus pyogenes*. In: Mandell GL, Bennett JE and Dolin R (eds), *Mandell, Douglas, Bennett's Principles and Practice of Infectious Diseases*, 6th ed. Elsevier Inc., Philadelphia, PA, 2005.
  72. Shaikh N, Leonard E, Martin JM. Prevalence of streptococcal pharyngitis and streptococcal carriage in children: a meta-analysis. *Pediatrics* 2010; 126:e557-64.
  73. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. *Lancet Infect Dis* 2005; 5: 685-94.

74. Stollerman GH, Dale JB. The importance of the group A streptococcus capsule in the pathogenesis of human infections: a historical perspective. *Clin Infect Dis* 2008; 46: 1038-45.
75. Passàli D, Lauriello M, Passàli GC, Passàli FM, Bellussi L. Group A streptococcus and its antibiotic resistance. *Acta Otorhinolaryngol Ital* 2007; 27: 27-32.
76. Aziz RK, Kotb M. Rise and persistence of global M1T1 clone of *Streptococcus pyogenes*. *Emerg Infect Dis* 2008; 14: 1511-7.
77. Baquero F, Blázquez J. Evolution of antibiotic resistance. *Trends Ecol Evol* 1997; 12: 482-7.
78. Granizo JJ, Aguilar L, Casal J, Dal-Ré R, Baquero F. *Streptococcus pyogenes* resistance to erythromycin in relation to macrolide consumption in Spain (1986-1997). *J Antimicrob Chemother* 2000; 46: 959-64.
79. Kataja J, Huovinen P, Muotiala A, Vuopio-Varkila J, Efstratiou A, Hallas G, Seppälä H. Clonal spread of group A streptococcus with the new type of erythromycin resistance. Finnish Study Group for Antimicrobial Resistance. *J Infect Dis* 1998; 177: 786-9.
80. Seppälä H, Klaukka T, Lehtonen R, Nenonen E, Huovinen P. Outpatient use of erythromycin: link to increased erythromycin resistance in group A streptococci. *Clin Infect Dis* 1995; 21: 1378-85.
81. Albertí S, García-Rey C, Domínguez MA, Aguilar L, Cercenado E, Gobernado M, García-Perea A; Spanish Surveillance Group for Respiratory Pathogens. Survey of *emm* gene sequences from pharyngeal *Streptococcus pyogenes* isolates collected in Spain and their relationship with erythromycin susceptibility. *J Clin Microbiol* 2003; 41: 2385-90.
82. Ardanuy C, Domenech A, Rolo D, Calatayud L, Tubau F, Ayats J, Martín R, Liñares J. Molecular characterization of macrolide- and multidrug-resistant *Streptococcus pyogenes* isolated from adult patients in Barcelona, Spain (1993-2008). *J Antimicrob Chemother* 2010; 65: 634-43.

83. Richter SS, Heilmann KP, Beekmann SE, Miller NJ, Miller AL, Rice CL, Doern CD, Reid SD, Doern GV. Macrolide-resistant *Streptococcus pyogenes* in the United States, 2002-2003. *Clin Infect Dis* 2005; 41: 599-608.
84. Chan JC, Chu YW, Chu MY, Cheung TK, Lo JY. Epidemiological analysis of *Streptococcus pyogenes* infections in Hong Kong. *Pathology* 2009; 41: 681-6.
85. Bley C, van der Linden M, Reinert RR. *mef(A)* is the predominant macrolide resistance determinant in *Streptococcus pneumoniae* and *Streptococcus pyogenes* in Germany. *Int J Antimicrob Agents* 2011; 37: 425-31.
86. Prieto J, Calvo A, Gómez-Lus ML. Antimicrobial resistance: a class effect?. *J Antimicrob Chemother* 2002; 50 (Suppl S2): 7-12.
87. Martin-Herrero JE, Garcia-Rey C, Dal-Ré R, Aguilar L. Clinical and bacteriological implications of macrolide resistance in group A streptococcal pharyngitis. *J Antimicrob Chemother* 2003; 52: 735-6.
88. Yan SS, Fox ML, Holland SM, Stock F, Gill VJ, Fedorko DP. Resistance to multiple fluoroquinolones in a clinical isolate of *Streptococcus pyogenes*: identification of *gyrA* and *parC* and specification of point mutations associated with resistance. *Antimicrob Agents Chemother* 2000; 44: 3196-8.
89. Biedenbach DJ, Toleman MA, Walsh TR, Jones RN. Characterization of fluoroquinolone-resistant beta-hemolytic *Streptococcus* spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant *Streptococcus dysgalactiae* subspecies *equisimilis*: report from the SENTRY Antimicrobial Surveillance Program (1997-2004). *Diagn Microbiol Infect Dis* 2006; 55: 119-27.
90. Richter SS, Diekema DJ, Heilmann KP, Almer LS, Shortridge VD, Zeitler R, Flamm RK, Doern GV. Fluoroquinolone resistance in *Streptococcus pyogenes*. *Clin Infect Dis* 2003; 36: 380-3.

91. Reinert RR, Lütticken R, Al-Lahham A. High-level fluoroquinolone resistance in a clinical *Streptococcus pyogenes* isolate in Germany. Clin Microbiol Infect 2004; 10: 659-62.
92. Malhotra-Kumar S, Van Heirstraeten L, Lammens C, Chapelle S, Goossens H. Emergence of high-level fluoroquinolone resistance in *emm6* *Streptococcus pyogenes* and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin. J Antimicrob Chemother 2009; 63: 886-94.
93. Smeesters PR, Vergison A, Junior DC, Van Melderren L. Emerging fluoroquinolone-non-susceptible group A streptococci in two different paediatric populations. Int J Antimicrob Agents 2009; 34: 44-9.
94. Albertí S, Cortés G, García-Rey C, Rubio C, Baquero F, García-Rodríguez JA, Bouza E, Aguilar L. *Streptococcus pyogenes* pharyngeal isolates with reduced susceptibility to ciprofloxacin in Spain: mechanisms of resistance and clonal diversity. Antimicrob Agents Chemother 2005; 49: 418-20.
95. Pires R, Ardanuy C, Rolo D, Morais A, Brito-Avô A, Gonçalo-Marques J, Liñares J, Santos-Sanches I. Emergence of ciprofloxacin-nonsusceptible *Streptococcus pyogenes* isolates from healthy children and pediatric patients in Portugal. Antimicrob Agents Chemother 2010; 54: 2677-80.
96. Montes M, Tamayo E, Orden B, Larruskain J, Perez-Trallero E. Prevalence and clonal characterization of *Streptococcus pyogenes* clinical isolates with reduced fluoroquinolone susceptibility in Spain. Antimicrob Agents Chemother 2010; 54: 93-7.
97. Billal DS, Hotomi M, Yan SS, Fedorko DP, Shimada J, Fujihara K, Yamanaka N. Loss of erythromycin resistance genes from strains of *Streptococcus pyogenes* that have developed resistance to levofloxacin. Diagn Microbiol Infect Dis 2009; 64: 225-8.
98. McGowan JE Jr, Gerding DN. Does antibiotic restriction prevent resistance?. New Horiz. 1996 Aug; 4(3): 370-6

99. Shlaes DM, Gerding DN, John JF Jr, Craig WA, Bornstein DL, Duncan RA et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the Prevention of Antimicrobial Resistance in Hospitals. *Infect Control Hosp Epidemiol* 1997; 18:275-291
100. Owens RC Jr, Ambrose PG. Antimicrobial stewardship and the role of pharmacokinetics-pharmacodynamics in the modern antibiotic era. *Diagn Microbiol Infect Dis*. 2007 Mar; 57(3 Suppl): 77S-83S
101. Aguilar L, Giménez MJ. Gaps in antibiotic development: the post-marketing task. *Rev Med Microbiol* 2008; 19:1-7
102. Drusano GL. Pharmacokinetics and pharmacodynamics of antimicrobials. *Clin Infect Dis*. 2007 Jul 15; 45 Suppl 1: S89-95
103. Jacobs MR. Combining resistance: application of the emerging science of pharmacokinetics and pharmacodynamics. *Int J Antimicrob Agents*. 2007 Dec; 30 Suppl 2: S122-6
104. Jacobs MRE. How can we predict bacterial eradication? *Int J Infect Dis*. 2003 Mar; 7 Suppl 1:S13-20
105. Grau S, Alvarez-Lerma F, Dominguez-Gil A. Pharmacokinetic/pharmacodynamic indices: are we ready to use them in daily practice? *Expert Rev Anti Infect Ther*. 2007 Dec; 5(6): 913-6
106. Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. *Clin Microbiol Rev* 2007; 20:391-408
107. Zeitlinger MA, Derendorf H, Mouton JW, Cars O, Craig WA, Andes D, Theuretzbacher U. Protein binding – do we ever learn?. *Antimicrob Agents Chemother* 2011 Jul; 55(7): 3067-74
108. Moellering RC, Eliopoulos GM. Principles of anti-infective therapy. In: Mandell GL, Bennett JE, Dolin R, editors. *Mandell, Douglas, and Bennett Principles and*

Practice of Infectious Diseases, 6<sup>th</sup> ed. Philadelphia: Elsevier Churchill Livingstone, 2005: 242-53

109. Olofsson SK, Cars O. Optimizing drug exposure to minimize selection of antibiotic resistance. *Clin Infect Dis*. 2007 Sept 1; 45 Supple 2: S129-36
110. Courvalin P. Can pharmacokinetic-pharmacodynamic parameters provide dosing regimens that are less vulnerable to resistance? *Clin Microbiol Infect* 2008 Nov; 14(11): 989-94
111. Prudhomme M, Attaiech L, Sanchez G, Martin B, Claverys JP. Antibiotic stress induces genetic transformability in the human pathogen *Streptococcus pneumoniae*. *Science* 2006 Jul 7; 313 (5783): 89-92
112. Wellington K, Curran MP. Cefditoren pivoxil: a review of its use in the treatment of bacterial infections. *Drugs* 2004; 64: 2597-2618
113. Yamada M, Watanabe T, Miyara T, et al. Crystal structure of cefditoren complexed with *Streptococcus pneumoniae* penicillin-binding protein 2X: structural basis for its high antimicrobial activity. *Antimicrob Agents Chemother* 2007; 51: 45-50.
114. Sábada B, Azanza JP, Quetglas EG, et al. Pharmacokinetic/pharmacodynamic serum and urine profile of cefditoren following single-dose and multiple twice- and thrice-daily regimens in healthy volunteers: a phase I study. *Rev Esp Quimioter* 2007; 20:51-60
115. Biedenbach DJ, Jones RN. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations. *Diagn Microbiol Infect Dis*. 2009; 64: 202-12.
116. Fritsche TR, Biedenbach DJ, Jones RN. Update of the activity of cefditoren and comparator oral beta-lactam agents tested against community-acquired *Streptococcus pneumoniae* isolates (USA, 2004-2006). *J Chemother*. 2008; 20: 170-4.

117. Stefani S, Mezzatesta ML, Fadda G, Mattina R, Palù G, Rossano F, Tufano MA, Schito GC, Nicoletti G. Antibacterial activity of cefditoren against major community-acquired respiratory pathogens recently isolated in Italy. *J Chemother* 2008; 20: 561-9.
118. Tempera G, Furneri PM, Ferranti C, Genovese C, Ripa S, Ungheri S, Nicoletti G. In vitro activity of cefditoren versus other antibiotics against *S. pneumoniae* clinical strains isolated in Italy. *Int J Immunopathol Pharmacol* 2010; 23: 833-40.
119. Tempera G, Furneri PM, Carlone NA, Cocuzza C, Rigoli R, Musumeci R, Pilloni AP, Prenna M, Tufano MA, Tullio V, Vitali LA, Nicoletti G. Antibiotic susceptibility of respiratory pathogens recently isolated in Italy: focus on cefditoren. *J Chemother* 2010; 22: 153-9.
120. Seral C, Suárez L, Rubio-Calvo C, Gómez-Lus R, Gimeno M, Coronel P, Durán E, Becerril R, Oca M, Castillo FJ. In vitro activity of cefditoren and other antimicrobial agents against 288 *Streptococcus pneumoniae* and 220 *Haemophilus influenzae* clinical strains isolated in Zaragoza, Spain. *Diagn Microbiol Infect Dis.* 2008; 62: 210-5.
121. Fenoll A, Giménez MJ, Robledo O, Coronel P, Gimeno M, Casal J, Aguilar L. Activity of cefditoren against clinical isolates of *Streptococcus pneumoniae* showing non-susceptibility to penicillins, cephalosporins, macrolides, ketolides or quinolones. *Int J Antimicrob Agents* 2007; 29: 224-6.
122. Fenoll A, Aguilar L, Robledo O, Giménez MJ, Tarragó D, Granizo JJ, Gimeno M, Coronel P. Influence of the beta-lactam resistance phenotype on the cefuroxime versus cefditoren susceptibility of *Streptococcus pneumoniae* and *Haemophilus influenzae* recovered from children with acute otitis media. *J Antimicrob Chemother* 2007; 60: 323-7.
123. Fenoll A, Giménez MJ, Robledo O, Aguilar L, Tarragó D, Granizo JJ, Martín-Herrero JE. Influence of penicillin/amoxicillin non-susceptibility on the activity of

- third-generation cephalosporins against *Streptococcus pneumoniae*. Eur J Clin Microbiol Infect Dis 2008; 27: 75-80.
124. Fenoll A, Giménez MJ, Robledo O, Aguilar L, Tarragó D, Granizo JJ, Gimeno M, Coronel P. In vitro activity of oral cephalosporins against pediatric isolates of *Streptococcus pneumoniae* non-susceptible to penicillin, amoxicillin or erythromycin. J Chemother 2008; 20: 175-9.
  125. Kozlow RS, Sivaya OV, Shevelev AN. Perspective of new cephalosporins for treatment of pneumococcal infections. Pulmonology 2011; 3: 53-8
  126. Soriano F, Granizo JJ, Fenoll A, Gracia M, Fernández-Roblas R, Esteban J, Gadea I, Coronel P, Gimeno M, Ródenas E, Santos F. Antimicrobial resistance among clinical isolates of *Streptococcus pneumoniae* isolated in four southern European countries (ARISE project) from adult patients: results from the cefditoren surveillance program. J Chemother 2003; 15: 107-12.
  127. Fenoll A, Aguilar L, Giménez MJ, Vicioso MD, Robledo O, Granizo JJ, Coronel P. Susceptibility of recently collected Spanish pneumococci nonsusceptible to oral penicillin from serotypes not included in the 7-valent conjugate vaccine. Antimicrob Agents Chemother 2010;54: 2696-8.
  128. Tarragó D, Aguilar L, García R, Gimenez MJ, Granizo JJ, Fenoll A. Evolution of clonal and susceptibility profiles of serotype 19A *Streptococcus pneumoniae* among invasive isolates from children in Spain (1990-2008). Antimicrob Agents Chemother. 2011; 55: 2297-302.
  129. Soriano F, Cafini F, Aguilar L, Tarragó D, Aloy L, Jiménez MJ, Gracia M, Ponte MC, Leu D, Pana M, Letowska I, Fenoll A. Breakthrough in penicillin resistance? *Streptococcus pneumoniae* isolates with penicillin/cefotaxime MICs of 16 mg/L and their genotypic and geographical relatedness. J Antimicrob Chemother 2008; 62: 1234-40.
  130. Sevillano D, Giménez MJ, Cercenado E, Cafini F, Gené A, Alou L, Marco F, Martínez-Martínez L, Coronel P, Aguilar L. Genotypic versus phenotypic



characterization, with respect to beta-lactam susceptibility, of *Haemophilus influenzae* isolates exhibiting decreased susceptibility to beta-lactam resistance markers. *Antimicrob Agents Chemother* 2009; 53: 267-70.

131. Gracia M, Díaz C, Coronel P, Gimeno M, García-Rodas R, del Prado G, Huelves L, Ruiz V, Naves PL, Ponte MC, Granizo JJ, Soriano F. Antimicrobial susceptibility of *Haemophilus influenzae* and *Moraxella catarrhalis* isolates in eight Central, East and Baltic European countries in 2005-06: results of the Cefditoren Surveillance Study. *J Antimicrob Chemother* 2008; 61: 1180-1.
132. Harimaya A, Yokota S, Sato K, Himi T, Fujii N. Remarkably high prevalence of *ftsI* gene mutations in *Haemophilus influenzae* isolates from upper respiratory tract infections in children of the Sapporo district, Japan. *J Infect Chemother* 2008; 14: 223-7.
133. García-de-Lomas J, Lerma M, Cebrián L, Juan-Bañón JL, Coronel P, Giménez MJ, Aguilar L. Influence of *Haemophilus influenzae* beta-lactamase production and/or *ftsI* gene mutations on in vitro activity of and susceptibility rates to aminopenicillins and second- and third-generation cephalosporins. *Int J Antimicrob Agents* 2007; 30: 190-2.
134. Biedenbach DJ, Jones RN, Fritsche TR. Antimicrobial activity of cefditoren tested against contemporary (2004-2006) isolates of *Haemophilus influenzae* and *Moraxella catarrhalis* responsible for community-acquired respiratory tract infections in the United States. *Diagn Microbiol Infect Dis* 2008; 61: 240-4.
135. Gracia M, Díaz C, Coronel P, Gimeno M, García-Rodas R, Rodríguez-Cerrato V, del Prado G, Huelves L, Ruiz V, Naves PF, Ponte MC, Granizo JJ, Soriano F. Antimicrobial susceptibility of *Streptococcus pyogenes* in Central, Eastern, and Baltic European Countries, 2005 to 2006: the cefditoren surveillance program. *Diagn Microbiol Infect Dis* 2009; 64: 52-6.

136. Casey JR, Pichichero ME. The evidence base for cephalosporin superiority over penicillin in streptococcal pharyngitis. *Diagn Microbiol Infect Dis* 2007; 57(3 Suppl.): S39-45.
137. Casey JR, Pichichero ME. Meta-analysis of cephalosporins versus penicillin for treatment of group A streptococcal tonsillopharyngitis in adults. *Clin Infect Dis* 2004; 38: 1526-34.
138. Sevillano D, Aguilar L, Alou L, Giménez MJ, González N, Torrico M, Cafini F, Fenoll A, Coronel P, Prieto J. High protein binding and cidal activity against penicillin-resistant *S. pneumoniae*: a cefditoren in vitro pharmacodynamic simulation. *PLoS One* 2008; 3(7): e2717.
139. Cafini F, Yuste J, Giménez MJ, Sevillano D, Aguilar L, Alou L, Ramos-Sevillano E, Torrico M, González N, García E, Coronel P, Prieto J. Enhanced in vivo activity of cefditoren in pre-immunized mice against penicillin-resistant *S. pneumoniae* (serotypes 6B, 19F and 23F) in a sepsis model. *PLoS One* 2010; 5 (8): e12041.
140. Luján M, Gallego M, Belmonte Y, Fontanals D, Vallès J, Lisboa T, Rello J. Influence of pneumococcal serotype group on outcome in adults with bacteremic pneumonia. *Eur Respir J.* 2010;36: 1073-1079.
141. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. *Clin Infect Dis* 1998;26: 1-10.
142. Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, Plouffe JF, Rakowsky A, Schuchat A, Whitney CG. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant *Streptococcus pneumoniae* Therapeutic Working Group. *Arch Intern Med* 2000; 160: 1399-1408.
143. Lodise TP, Kinzig-Schippers M, Drusano GL, Loos U, Vogel F, Bulitta J, Hinder M, Sörgel F. Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid. *Antimicrob Agents Chemother* 2008; 52: 1945-1951.

144. Food and Drug Administration. Spectracef prescribing information. <http://www.crtx.com/docs/spectracef.pdf>
145. Granizo JJ, Sádaba B, Honorato J, Gimenez MJ, Sevillano D, Aguilar L, Coronel P. Monte Carlo simulation describing the pharmacodynamic profile of cefditoren in plasma from healthy volunteers. *Int J Antimicrob Agents* 2008;31: 396-398.
146. Karlowsky JA, Jones ME, Draghi DC, Critchley IA, Thornsberry C, Sahm DF. In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren. *Diagn Microbiol Infect Dis* 2002;42: 59-64.
147. Johnson DM, Biedenbach DJ, Beach ML, Pfaller MA, Jones RN. Antimicrobial activity and in vitro susceptibility test development for cefditoren against *Haemophilus influenzae*, *Moraxella catarrhalis*, and *Streptococcus* species. *Diagn Microbiol Infect Dis* 2000;37: 99-105.
148. Jones RN, Biedenbach DJ, Croco MA, Barrett MS. In vitro evaluation of a novel orally administered cephalosporin (Cefditoren) tested against 1249 recent clinical isolates of *Haemophilus influenzae*, *Moraxella catarrhalis*, and *Streptococcus pneumoniae*. *Diagn Microbiol Infect Dis* 1998; 31: 573-578.
149. Agencia Española de Medicamentos y Productos Sanitarios. <https://sinaem4.agemed.es/consaem/fichasTecnicas.do?metodo=detalleForm>
150. Brook I. The role of beta-lactamase producing bacteria and bacterial interference in streptococcal tonsillitis. *Int J Antimicrob Agents* 2001; 17: 439-442.
151. Musher DM. *Streptococcus pneumoniae*. In: Mandell GL, Bennett JE, Dolin R, editors. *Mandell, Douglas, and Bennett Principles and Practice of Infectious Diseases*, 6<sup>th</sup> ed. Philadelphia: Elsevier Churchill Livingstone, 2005: 2392-2411.
152. Murphy TF. *Haemophilus influenzae*. In: Mandell GL, Bennett JE, Dolin R, editors. *Mandell, Douglas, and Bennett Principles and Practice of Infectious Diseases*, 6<sup>th</sup> ed. Philadelphia: Elsevier Churchill Livingstone, 2005: 2661-2669.

153. Smith-Vaughan HC, Leach AJ, Shelby-James TM, Kemp K, Kemp DJ, Mathews JD. Carriage of multiple ribotypes of non-encapsulated *Haemophilus influenzae* in aboriginal infants with otitis media. *Epidemiol Infect* 1996;116: 177-183.
154. Sá-Leão R, Nunes S, Brito-Avô A, Alves CR, Carriço JA, Saldanha J, Almeida JS, Santos-Sanches I, de Lencastre H. High rates of transmission of and colonization by *Streptococcus pneumoniae* and *Haemophilus influenzae* within a day care center revealed in a longitudinal study. *J Clin Microbiol* 2008; 46: 225-234.
155. Takahata S, Ida T, Senju N, Sanbongi Y, Miyata A, Maebashi K, Hoshiko S. Horizontal gene transfer of *ftsI*, encoding penicillin-binding protein 3, in *Haemophilus influenzae*. *Antimicrob Agents Chemother* 2007; 51: 1589-1595.
156. González N, Aguilar L, Sevillano D, Giménez MJ, Alou L, Cafini F, Torrico M, López AM, Coronel P, Prieto J. Efficacy of simulated cefditoren versus amoxicillin-clavulanate free concentrations in countering intrastrain *ftsI* gene diffusion in *Haemophilus influenzae*. *Antimicrob Agents Chemother* 2011; 55: 2788-2794.
157. González N, Aguilar L, Alou L, Giménez MJ, Sevillano D, Torrico M, Cafini F, Coronel P, Prieto J. Influence of different resistance traits on the competitive growth of *Haemophilus influenzae* in antibiotic-free medium and selection of resistant populations by different  $\beta$ -lactams: an in vitro pharmacodynamic approach. *J Antimicrob Chemother* 2009; 63: 1215-1222.
158. Cafini F, Aguilar L, Sevillano D, Giménez MJ, Alou L, Fenoll A, Echevarría O, Torrico M, González N, Coronel P, Prieto J. Decrease in bacterial load versus resistance selection of pneumococcal subpopulations by beta-lactam physiological concentrations over time: an in vitro pharmacodynamic simulation. *Microb Drug Resist* 2008; 14: 13-21.
159. Sevillano D, Aguilar L, Alou L, Giménez MJ, González N, Torrico M, Cafini F, Coronel P, Prieto J. Beta-lactam effects on mixed cultures of common

respiratory isolates as an approach to treatment effects on nasopharyngeal bacterial population dynamics. PLoS One 2008; 3: e3846.

160. Granizo JJ, Giménez MJ, Barberán J, Coronel P, Gimeno M, Aguilar L. Efficacy of cefditoren in the treatment of upper respiratory tract infections: a pooled analysis of six clinical trials. Rev Esp Quimioter 2008; 21: 14-21.
161. Granizo JJ, Giménez MJ, Barberán J, Coronel P, Gimeno M, Aguilar L. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by *Streptococcus pneumoniae* and *Haemophilus influenzae*: a pooled analysis of seven clinical trials. Clin Ther 2006; 28: 2061-2069.